Tracking survival: how a cancer drug performs in everyday practice
NCT ID NCT05034926
Summary
This study observed how well patients with advanced non-small cell lung cancer lived after receiving the drug nivolumab in real-world clinics in Greece and Cyprus. It followed 212 patients who had already tried chemotherapy, tracking their survival at 1, 2, and 3 years, their quality of life, and side effects. The goal was to understand how this treatment works outside of strict clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Athens, 11527, Greece
-
Local Institution - 0002
Stróvolos, 2012, Cyprus
Conditions
Explore the condition pages connected to this study.